Mineralys Therapeutics
is a Pennsylvania-based clinical-stage biopharmaceutical that develops and commercializes novel therapeutics for the treatment of hypertension... Read moreMineralys Therapeutics
is a Pennsylvania-based clinical-stage biopharmaceutical that develops and commercializes novel therapeutics for the treatment of hypertension... Read more
2020
PublicIndependent CompanyNASDAQMLYS
News
Apr 06, 2025
Medthority
Mineralys Therapeutics: Lorundrostat Phase II Results
Mar 30, 2025
Life Care News
Mineralys Therapeutics: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiologys Annual Scientific Session & Expo (ACC.25)
Mar 25, 2025
Marketscreener
Mineralys Therapeutics: Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Mar 17, 2025
Benzinga
Mineralys Therapeutics: Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
Mar 10, 2025
Endpoints News
Mineralys Therapeutics: Mineralys' Phase 3 blood pressure pill data support potential FDA approval
Mar 10, 2025
RTTNews
Mineralys Therapeutics: Mineralys' Pivotal Launch-HTN Phase 3, Advance-HTN Phase 2 Studies Meet Primary Goals; Stock Up
Mar 10, 2025
Clinical Trials Arena
Mineralys Therapeutics: Mineralys's stock soars as hypertension pill scores in two pivotal trials
Mar 10, 2025
The Business Journals: Philadelphia
Mineralys Therapeutics: Mineralys Therapeutics' stock price explodes after lorundrostat study results
Mar 10, 2025
Seeking Alpha
Mineralys Therapeutics: Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Mar 10, 2025
BioSpace
Mineralys Therapeutics: Mineralys' Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash
